And recently at one of the meetings it was presented, this is Steven Horvath that we had on Ground Truths not long ago
Current approved indications are limited to type 2 diabetes mellitus and chronic weight management (for specific agents at designated doses)
Common starting dose mistakes Years of community experience with GLP-1 agonists have revealed patterns of mistakes that repeat across different peptides
Cost Burden Analysis: To calculate the income burden faced in each state, we compared the average monthly out-of-pocket price of GLP-1 medications (pricing assumptions reflect a blended cash-pay range of approximately $150$450 per month, with $350 used as a common injectable reference point rather than a universal baseline) to each states per capita annual income
now had for weight loss turned into an episode of vertigo accompanied by cardiac symptoms and a hospitalization for evaluation
Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ